Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints


Based on discussions with the FDA, the Company plans to submit a Biologics License......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Tuesday, 22 October

Share |